Solid Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 13, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 13, 2024

SLDB$7.02+6.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SOLID BIOSCIENCES INC.
Date: March 13, 2024	By:	/s/ Alexander Cumbo
		Alexander CumboPresident, Chief Executive Officer and Director(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Ilan Ganot
/s/ Alexander Cumbo Alexander Cumbo	President, Chief Executive Officer and Director(Principal Executive Officer)	March 13, 2024
/s/ Kevin Tan Kevin Tan	Chief Financial Officer(Principal Financial and Accounting Officer)	March 13, 2024
/s/ Ian F. Smith Ian F. Smith	Chairman of the Board	March 13, 2024
/s/ Martin Freed Martin Freed	Director	March 13, 2024
/s/ Ilan Ganot	Director	March 13, 2024
/s/ Clare Kahn	Director	March 13, 2024
Clare Kahn
/s/ Georgia Keresty	Director	March 13, 2024
Georgia Keresty
/s/ Adam Koppel Adam Koppel	Director	March 13, 2024
/s/ Sukumar Nagendran Sukumar Nagendran	Director	March 13, 2024
/s/ Rajeev Shah Rajeev Shah	Director	March 13, 2024
/s/ Adam Stone Adam Stone	Director	March 13, 2024
/s/ Lynne Sullivan Lynne Sullivan	Director	March 13, 2024

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.